Drug Profile
Research programme: FAK/VEGFR3 inhibitors - CureFAKtor Pharmaceuticals
Alternative Names: C10; C9; C9A; CFAK-C10; CFAK-C4; CFAK-C9; CFAK-C9a; CFAK-Y15; Chloropyramine; Chloropyramine hydrochloride; FAK inhibitors - CureFAKtor; FAK technology platform - CureFAKtor; Y15Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CureFAKtor Pharmaceuticals
- Class Small molecules
- Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer; Solid tumours
Most Recent Events
- 03 May 2016 No recent reports on development identified - Preclinical for Solid tumours and Pancreatic cancer in USA (PO)
- 14 Nov 2011 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011) ,,
- 23 Jun 2011 Pharmacodynamics data from a preclinical trial in Pancreatic cancer presented at the 16th European Cancer Conference and the 36th Congress of the European Society for Medical Oncology (ECCO/ESMO-2011)